Grant Publications

Proposal No.   IBD-0076
Principal Investigator:  Dirk Föll, M.D.
Applicant Organization:  University Hospital of Münster (Germany)
Project Title: The role of the receptor for advanced glycation end products (RAGE) and its ligand S100A12 (EN-RAGE) in chronic inflammatory bowel disease
Period of Award:  November 1, 2003 – June 30, 2006

Srikrishna G, Turovskaya O, Shaikh R, Newlin R, Foell D, Murch S, Kronenberg M, Freeze HH.  Carboxylated glycans mediate colitis through activation of NF-kappa B.  The Journal of Immunology 2005;175:5412-22.

Foell D, Wittkowski H, Vogl T, Roth J.  S100 proteins expressed in phagocytes:  a novel group of damage associated molecular pattern molecules.  Journal of Leukocyte Biology 2007;81:28-37.

Foell D, Wittkowski H, Roth J.  Mechanisms of disease: A DAMP view on arthritis. Nature Clinical Practice Rheumatology 2007;3:382-90.

Kaiser T, Langhorst J, Wittkowski H, Becker K, Friedrich AW, Rueffer A, Dobos GJ, Roth J, Foell D.  Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome. Gut 2007;56:1706-13.

Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA, Nacken W, Foell D, van der Poll T, Sorg C, Roth J.  Mrp8 and Mrp14 are endogenous activators of Toll-like receptor 4, promoting lethal, endotoxin-induced shock.  Nature Medicine 2007;13:1042-9.

Wittkowski H, Sturrock A, van Zoelen MAD, Viemann D, van der Poll T, Hoidal JR, Roth J, Foell D.  Neutrophil-derived S100A12 in acute lung injury and respiratory distress syndrome.  Critical Care Medicine 2007;35:1369-75.